Re: Final results of sequential doxorubicin plus gemcita-bine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium

摘要

Experts' comments:It seemed that the conquest of transitional cell carcinomas was at hand when BCG entered the clinic as a promising agent to avoid recurrence, and serial studies demonstrated that combination chemotherapy resulted in complete remission with significant prolongation of disease-fee survival. We then shared the vision that early diagnosis followed by chemotherapy would lead to curative bladder-sparing treatment. Our hopes were not realized. In contrast to what has occurred in other common adult solid tumors, we have seen no survival improvement for patients with urothelial cancers.